Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations-Reference-Cited by-同舟云学术

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations

Published:2023-08-04 Issue:8 Volume:11 Page:1320
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Hyun Hak-Jun¹,Choi Min-Joo²,Nham Eliel³⁴⁵,Seong Hye³⁴⁵,Yoon Jin-Gu³⁴⁵^ORCID,Noh Ji-Yun³⁴⁵,Cheong Hee-Jin³⁴⁵,Kim Woo-Joo³⁴⁵^ORCID,Yoon Sun-Kyung⁶,Park Se-Jin⁶,Gwak Won-Seok⁶,Lee June-Woo⁶,Kim Byoung-Guk⁶,Song Joon-Young³⁴⁵^ORCID

Affiliation:

1. Department of Infectious Diseases, Ajou University School of Medicine, Suwon 16499, Republic of Korea

2. Department of Internal Medicine, International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon 22711, Republic of Korea

3. Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea

4. Asia Pacific Influenza Institute, Korea University College of Medicine, Seoul 02841, Republic of Korea

5. Vaccine Innovation Center-KU Medicine (VIC-K), Seoul 02841, Republic of Korea

6. Division of Vaccine Clinical Research, Center for Vaccine Research National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju 28159, Republic of Korea

Abstract

Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants (BA.1, BA.5, BQ.1.1, BN.1, and XBB.1) before and 3–4 weeks after bivalent booster by the types of SARS-CoV-2 variants in prior infections and bivalent vaccine formulations. A total of 21 participants were included. Prior BA.1/BA.2-infected, and BA.5-infected participants showed significantly higher geometric mean titers of Nab compared to SARS-CoV-2-non-infected participants after bivalent booster (BA.1, 8156 vs. 4861 vs. 1636; BA.5, 6515 vs. 4861 vs. 915; BQ.1.1, 697 vs. 628 vs. 115; BN.1, 1402 vs. 1289 vs. 490; XBB.1, 434 vs. 355 vs. 144). When compared by bivalent vaccine formulations, Nab titers against studied subvariants after bivalent booster did not differ between BA.1 and BA.4/BA.5 bivalent vaccine (BA.1, 4886 vs. 5285; BA.5, 3320 vs. 4118; BQ.1.1, 311 vs. 572; BN.1, 1028 vs. 1095; XBB.1, 262 vs. 362). Both BA.1 and BA.4/BA.5 bivalent vaccines are immunogenic and provide enhanced neutralizing activities against Omicron subvariants. However, even after the bivalent booster, neutralizing activities against the later Omicron strains (BQ.1.1, BN.1, and XBB.1) would be insufficient to provide protection.

Funder

Korea Disease Control and Prevention Agency

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/8/1320/pdf

Reference30 articles.

1. World Health Organization (2023, June 30). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available online: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

2. World Health Organization (2023, June 30). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/region/wpro/country/kr.

3. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: Findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022;Wu;Lancet Respir. Med.,2023

4. Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study;Kim;J. Korean Med. Sci.,2023

5. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression;Bobrovitz;Lancet Infect. Dis.,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea;Osong Public Health and Research Perspectives;2024-08-31

2. Requirement of the N-terminal region of nonstructural protein 1 in cis for SARS-CoV-2 defective RNA replication;Journal of Virology;2024-08-28

3. Durability of SARS-CoV-2 IgG Antibodies: Insights from a Longitudinal Study, Puerto Rico;2024-08-03

4. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants;Vaccine;2024-05

5. A Systematic Review and Meta-Analysis on the Effectiveness of Bivalent mRNA Booster Vaccines against Omicron Variants;2024-01-11